Dashboards for Microsoft/Bing Ads campaigns in Healthcare / Pharma show clicks, impressions and conversions, but they rarely show how much of that spend actually reached a real patient, HCP or procurement contact. Lunio's invalid traffic data layer exists to close that gap, showing what share of reported performance is reaching genuine buyers rather than bots. Find out how much of your Microsoft/Bing Ads budget is being wasted →
Healthcare / Pharma on Microsoft Ads operates in a smaller, lower-competition auction than Google, reaching an audience that skews older, more affluent, and more desktop-based. That audience profile, combined with Microsoft's LinkedIn Profile Targeting overlay, makes the platform a genuinely distinctive channel for reaching NHS and pharma procurement contacts rather than a cheaper clone of Google Search.
Because neither Microsoft Ads nor Healthcare / Pharma is yet covered in Lunio's proprietary 2026 dataset, the table below uses the platform-level invalid traffic rate as a baseline reference and the most defensible external CPC estimates available, flagged by data vintage.
| Campaign Type | IVT Rate | CPC |
|---|---|---|
| Search (Microsoft Search Network) | 10.32% (platform-level) | $2.00–$5.00 (2026 estimate) |
| Microsoft Audience Network | 10.32% (platform-level) | Not separately benchmarked |
| Performance Max | 10.32% (platform-level) | Not separately benchmarked |
Bing holds roughly 11.78% of global desktop search share against just 0.52% of mobile search share, per Amra and Elma's 2026 Bing Ads statistics roundup, and healthcare searches skew further toward desktop given the concentration of NHS and institutional users on managed corporate devices. For Pharma B2B specifically, procurement and formulary research happens almost entirely on desktop, during work hours, on Windows machines where Bing is the default search engine.
The CPC estimate above isn't meaningfully split by device for Healthcare / Pharma, since no source publishes a mobile versus desktop CPC breakdown for this combination. What the desktop skew does change is intent quality: a healthcare search on a managed corporate device during work hours is more likely to represent a genuine research session than a mobile search, even without a formal device split to confirm it. CPM remains unpublished for this combination; Microsoft Audience Network inventory is priced on a CPM basis, but no source tracks it separately for Healthcare or Pharma.
Neither Microsoft/Bing Ads nor Healthcare / Pharma is currently covered in Lunio's proprietary 2026 dataset, so every invalid traffic figure in this article is a platform-level or cross-industry reference point, not a figure observed specifically for Healthcare / Pharma campaigns on Microsoft Ads. The CPC, CTR, and CPA figures are drawn from the Deep Research Briefing's external sources (WordStream, Benchmarketing, Priority Pixels, Promodo) and are flagged by vintage throughout, since the most-cited Bing healthcare benchmarks trace back to a single 2017 dataset. For the IVT figures specifically, the baseline is the Lunio 2026 Global Invalid Traffic Report. Calculate how much you're losing →
Healthcare / Pharma advertisers on Microsoft Ads typically run three or four campaign types side by side, each with a different exposure profile. Here's how invalid traffic risk and available cost data differ across them.
Search (Microsoft Search Network): This is where almost all Healthcare / Pharma spend sits, covering Bing.com, Yahoo, DuckDuckGo, and AOL. The platform-level invalid traffic rate here is 10.32%, per Lunio's invalid traffic rates by ad platform data, but Healthcare / Pharma is overwhelmingly a lead-gen vertical, with the conversion event almost always an appointment request, consultation booking, or whitepaper download rather than a transaction. Lead-gen models carry a 32.07% higher invalid traffic rate than transactional models, per the Lunio 2026 Global Invalid Traffic Report, a cross-vertical finding rather than a Microsoft Ads Healthcare-specific figure, but directly relevant given how this vertical converts. The Microsoft Advertising Traffic Quality Center does filter general invalid traffic, known crawlers and data centre IP ranges, before billing closes, and that protection is real. It isn't designed to catch sophisticated invalid traffic such as advanced bots simulating a human filling out an appointment form, which is precisely the conversion event most valuable to simulate in Healthcare / Pharma lead-gen.
Microsoft Audience Network: No source publishes a Microsoft-specific invalid traffic rate for native display placements across MSN, Outlook.com, and Edge. As a directional reference only, Google's equivalent display inventory runs at 12.02% IVT against 5.21% for Google Search, so Healthcare / Pharma advertisers running Audience Network alongside Search should expect a meaningfully higher exposure on the display side, even without a Microsoft-specific figure to confirm the exact gap.
LinkedIn Profile Targeting: This overlay, unique to Microsoft Ads, layers job title, company, and seniority targeting onto search campaigns and is the platform's strongest asset for reaching NHS procurement teams and pharma HCP audiences. No invalid traffic figure exists for this targeting layer specifically, but the professional-network data behind it should, in principle, filter out some of the anonymous bot and click-farm traffic that affects broad keyword targeting.
Performance Max: Still too new on Microsoft Ads for any Healthcare-specific benchmark data to exist. Advertisers testing it should treat early CPA and CVR numbers cautiously until several months of data accumulate.
| Country | IVT Rate |
|---|---|
| United States | 8.44% |
| United Kingdom | 7.97% |
| Germany | 6.34% |
| France | 6.63% |
| Australia | 7.87% |
| Canada | 6.29% |
The US combines the highest IVT rate of the six markets, 8.44%, with the largest healthcare advertising spend, making it the single highest-risk market for Healthcare / Pharma budgets on Microsoft Ads. The UK follows at 7.97% IVT, and Priority Pixels' estimate of £3 to £6 CPC for UK healthcare keywords means the combination of above-average cost and above-average IVT applies there too, particularly for NHS-adjacent private healthcare campaigns. Germany and Canada offer the most relative efficiency in this group, each sitting below 6.4% IVT, though neither has published CPC data specific to Healthcare / Pharma on Microsoft Ads. See Lunio's ad fraud data by country for the full country-level methodology.
Take a Healthcare / Pharma advertiser spending $120,000 a year on Microsoft Ads, a realistic mid-size budget given a typical 10 to 20% allocation of total paid search spend to the platform. At the platform-level invalid traffic rate of 10.32%, per the Lunio 2026 Global Invalid Traffic Report, that's $12,384 spent on clicks that never had a chance of becoming a genuine patient or HCP lead. Scale that to a $500,000 annual Microsoft Ads budget and the same rate works out to $51,600 wasted before a single fake appointment request or spam contact form even reaches the CRM.
Because Healthcare / Pharma converts almost entirely through lead-gen actions, form fills, appointment requests, consultation bookings, the 32.07% higher invalid traffic rate Lunio observes for lead-gen models against transactional ones suggests actual exposure for this vertical likely sits above the platform-level baseline rather than at it, consistent with the lead-gen risk patterns documented in Lunio's invalid traffic statistics by industry. Lunio's work with Funding Circle, a lead-generation advertiser running paid search across Google and Microsoft Ads, offers the closest available proxy for what cleaning this up looks like in practice: reducing average invalid traffic rate by 81.41% (from 16.84% to 3.13%), saving 5.8% of spend across Google and Microsoft Ads combined, and lifting MQL conversion rate by 10%, per Lunio's Funding Circle case study. It isn't a Healthcare account, but the lead-gen structure and the Microsoft Ads channel are directly comparable.
Start your free 14-day traffic audit with Lunio →
Every CPC, CTR, CVR, and CPA figure in this article tells you what the market reports, not what your budget actually delivers. Invalid traffic is the gap between the two, and for a lead-gen vertical like Healthcare / Pharma running on a lower-volume platform like Microsoft Ads, even a handful of fake form fills a month can be enough to bias Smart Bidding toward the wrong traffic sources for weeks at a time. Lunio measures that gap directly, on your account, rather than leaving you to extrapolate it from a platform average.
Start your free 14-day traffic audit with Lunio →
The only Bing-specific figure available is WordStream's $1.70 median for "Health & Wellness," collected in Q3 2017 and now nine years old. Priority Pixels' 2026 UK estimate of £3 to £6 for healthcare keywords suggests CPC has risen substantially since then, putting a reasonable 2026 estimate at $2.00 to $5.00, though this range is extrapolated rather than directly observed.
A 3.8% median CTR, calibrated against appointment-request conversions from Q1 2023 to Q4 2024, is a reasonable target, with top-quartile accounts reaching 6.4%. A CTR well above top quartile, especially on Microsoft Audience Network placements, is worth investigating rather than celebrating, since inflated CTR can come from bot clicks on native ad units rather than genuine patient or HCP interest.
Benchmark datasets like WordStream's weren't filtered for invalid traffic, so the CPC, CVR, and CPA figures they report include whatever proportion of bot and click-farm activity was present in those accounts at the time. If your own account's conversion data includes fake appointment requests or spam form fills, your reported CPA will look better than your real cost per genuine lead, and your Smart Bidding strategy will be learning from contaminated signals.
The US runs the highest invalid traffic rate among major markets at 8.44%, compared with 6.34% in Germany, 6.63% in France, and 6.29% in Canada, per Lunio's verified country-level data. The UK sits closer to the US at 7.97%, which matters for Healthcare / Pharma advertisers running NHS-adjacent or private UK healthcare campaigns on Microsoft Ads.